On Tuesday, Evolus Inc (NASDAQ: EOLS) opened lower -3.37% from the last session, before settling in for the closing price of $9.80. Price fluctuations for EOLS have ranged from $9.48 to $17.82 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 55.81%. Company’s average yearly earnings per share was noted 65.65% at the time writing. With a float of $54.70 million, this company’s outstanding shares have now reached $63.25 million.
Considering the fact that the conglomerate employs 273 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 68.25%, operating margin of -13.69%, and the pretax margin is -22.2%.
Evolus Inc (EOLS) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Evolus Inc is 13.62%, while institutional ownership is 79.75%. The most recent insider transaction that took place on Dec 23 ’24, was worth 24,438. In this transaction an insider of this company sold 2,252 shares at a rate of $10.85, taking the stock ownership to the 366,595 shares. Before that another transaction happened on Dec 23 ’24, when Company’s Chief Financial Officer sold 1,586 for $10.85, making the entire transaction worth $17,211. This insider now owns 146,916 shares in total.
Evolus Inc (EOLS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 65.65% per share during the next fiscal year.
Evolus Inc (NASDAQ: EOLS) Trading Performance Indicators
Check out the current performance indicators for Evolus Inc (EOLS). In the past quarter, the stock posted a quick ratio of 2.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.91, a number that is poised to hit 0.02 in the next quarter and is forecasted to reach -0.06 in one year’s time.
Technical Analysis of Evolus Inc (EOLS)
Compared to the last year’s volume of 0.89 million, its volume of 0.85 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 10.87%. Additionally, its Average True Range was 0.56.
During the past 100 days, Evolus Inc’s (EOLS) raw stochastic average was set at 2.57%, which indicates a significant decrease from 9.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.99% in the past 14 days, which was lower than the 51.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.37, while its 200-day Moving Average is $13.34. Nevertheless, the first resistance level for the watch stands at $9.82 in the near term. At $10.18, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.46. If the price goes on to break the first support level at $9.18, it is likely to go to the next support level at $8.90. Should the price break the second support level, the third support level stands at $8.54.
Evolus Inc (NASDAQ: EOLS) Key Stats
There are currently 63,321K shares outstanding in the company with a market cap of 599.65 million. Presently, the company’s annual sales total 202,090 K according to its annual income of -61,690 K. Last quarter, the company’s sales amounted to 61,090 K and its income totaled -19,170 K.
